Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06287320

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Locally Advanced Non-small Cell Lung Cancer Clinical Trial

Official title:
The Peripheral Blood Lymphocyte Subsets as Predicative Biomarkers Reflecting the Efficacy and Toxicity in Patients With Locally Advanced Non-small Cell Lung Cancer Received Chemoradiotherapy With or Without Immunotherapy

Clinical Trial Summary

This study is a prospective cohort study to evaluate the peripheral blood lymphocyte subsets as predicative biomarkers reflecting the efficacy and toxicity in patients with locally advanced non-small cell lung cancer (NSCLC) received chemoradiotherapy (CRT) with or without immune checkpoint inhibitors (ICIs).

Clinical Trial Description

All patients had a pathologically confirmed locally advanced NSCLC according to the 8th AJCC staging system and received definitive radiotherapy, concurrently or sequentially combined with platinum-based doublet chemotherapy. The peripheral blood samples at various time points including before radiation, 4 weeks after beginning of radiation, the end of radiation, 1 month post radiation, and 1 month post consolidation immunotherapy were collected for lymphocyte subsets detection. The subjects will be divided into two groups according to whether patients received ICIs, namely, NSCLC patients received CRT plus ICIs and NSCLC patients received CRT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06287320
Study type Observational
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Nan Bi, MD
Phone 8601087788799
Email binan_email@163.com
Status Recruiting
Phase
Start date March 1, 2024
Completion date February 28, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2
Recruiting NCT05339568 - Patient's Whole Process Follow-up Management(HOPE-1)
Recruiting NCT04749394 - A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy Phase 2
Completed NCT01537991 - ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial N/A
Completed NCT04648033 - Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC Phase 1
Completed NCT01059552 - Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 1
Not yet recruiting NCT04153734 - Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC Phase 2
Completed NCT03371550 - A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy Phase 2
Terminated NCT00614484 - Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05620199 - Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy N/A
Withdrawn NCT05481775 - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Phase 2